Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Weekly GS-1720 + GS-4182 vs Biktarvy in Treatment‑Naive HIV-1
2024-512505-66-00Phase 3Completed
- Sponsor
- Gilead Sciences
- Start
- Feb 2025
- Modality
- Small Molecules
- Countries
- 14
01
Overview
Phase 3, randomised trial in human immunodeficiency virus infection (HIV) comparing Weekly GS-1720 + GS-4182 with Biktarvy once daily (2 arms). Started Feb 2025; status: completed.
02
Drugs
lepetegravirlenacapavir pacfosacilbictegravir + emtricitabine + tenofovir alafenamide
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on 2024-512505-66-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-512505-66-00.